Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4006896 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A LY4006896 + Placebo | EXPERIMENTAL | Healthy participants will receive a single escalating dose of LY4006896 and matching placebo. |
| Part B LY4006896 + Placebo | EXPERIMENTAL | Participants with Parkinson's disease will receive multiple escalating doses of LY4006896 and matching placebo. |
| Name | Type | Description |
|---|---|---|
| LY4006896 | DRUG | Administered intravenously (IV) |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: Part A Single Ascending Dose (SAD) and B Multiple Ascending Dose (MAD) * Have a body mass index within the range of 18 to 34 kilogram/square meter (kg/m²) (inclusive). * For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant,...
LY4006896 is an investigational small molecule being developed for Parkinson's disease. It is currently in Phase 1 clinical development, with a study enrolling healthy participants and participants with Parkinson's disease. The drug is being studied in the United States and Japan.
LY4006896 is being developed by Eli Lilly and Company (NYSE: LLY). The company is conducting a Phase 1 clinical trial of the drug in healthy participants and participants with Parkinson's disease.
LY4006896 is in Phase 1 clinical development. The drug is being evaluated in an early-stage study that is currently recruiting participants. It is not yet approved and remains investigational.
LY4006896 is being studied in a Phase 1 trial with the identifier NCT06809400. The trial, titled "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease," is recruiting 127 participants in the United States and Japan.
Yes, LY4006896 is being studied in healthy volunteers as part of its Phase 1 clinical trial. The study also includes participants with Parkinson's disease, with a minimum age of 30 years for enrollment.